From the Office of Dr. Pedram Mizani, MD, MHSA President & Chief Clinical Officer | acmedical.org Former Chief Medical Resident | Morehouse School of Medicine Family Medicine Residency

Last updated: May 4, 2020 at 4:50 AM PST

PPE Breaking News: 6,000 KN95/FFP2 (comparable to NIOSH approved N95) face masks were delivered to AmeriClerkships for our Members to use during their upcoming US clinical rotations, and for donations to our affiliated healthcare facilities in need. Read more.

The World Health Organization is maintaining a data repository on various research and development efforts for the treatment and prevention of COVID-19 globally.

They include:

Below are some interesting updates from notable US teaching hospitals and medical schools:

NBC News: “The Food and Drug Administration will allow doctors across the country to begin using plasma donated by coronavirus survivors to treat patients who are critically ill with the virus, under new emergency protocols approved Tuesday.” The “decision comes a day after New York Gov. Andrew Cuomo announced that the state’s health department planned to begin treating the sickest coronavirus patients with antibody-rich plasma extracted from the blood of those who’ve recovered. The treatment, known as convalescent plasma, dates back centuries and was used during the flu pandemic of 1918, in an era before modern vaccines and antiviral drugs. Some experts have argued that it might be the best hope for combating the coronavirus until more sophisticated therapies can be developed, which could take several months.”

The Hill: “The FDA has approved emergency protocols that allow doctors to request permission on a case-by-case basis for coronavirus patients. The plasma treatment will be exclusively used for patients who are close to death, with the FDA responding to most requests within four to eight hours and doctors having the option to contact the FDA’s Office of Emergency Operations for more time-sensitive cases.”

NPR: Called it “an unusual move,” and says that “there is scant evidence it works in people infected with the coronavirus, but the approach has been tried for other illnesses.”

The first Southern California research using Giliad’s Remdesivir, at University of California Irvine: